Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Sponsor: Genentech, Inc.
Terminated
Slow accrual; toxicity; change in priorities
Other terminated trials from Genentech, Inc.
- Idiopathic Pulmonary Fibrosis · Phase PHASE2 · Jan 2026
- Non-small Cell Lung Cancer · Phase PHASE2 · Nov 2025
- Solid Tumour · Phase PHASE1 · Nov 2025
- Diffuse Large B-cell Lymphoma · Oct 2025
- Ulcerative Colitis · Phase PHASE2 · Jun 2025
More terminations from Genentech, Inc.
Listed as NCT01495988, this PHASE2 trial focuses on Melanoma and Metastatic Melanoma and remains terminated or withdrawn. Sponsored by Genentech, Inc., it has been updated 12 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
▶ Show 7 earlier versions
-
Dec 2021 — Dec 2022 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Nov 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Aug 2017 — Nov 2017 [monthly]
Terminated PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Aug 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Genentech, Inc.
- Melanoma Research Foundation Breakthrough Consortium
For direct contact, visit the study record on ClinicalTrials.gov .